2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/2iy5wruuedsh6.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/00yc7rcvua6a7.js","/_next/static/immutable/chunks/37ktb71aq3480.js","/_next/static/immutable/chunks/2d50b-7eu4558.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/2d6noqpp6ehas.js","/_next/static/immutable/chunks/1sx186c93bpzg.js","/_next/static/immutable/chunks/3dc-1n866s65i.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2w1bvggzb0ga8.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T60a,The study was designed to obtain a preliminary assessment of the safety and efficacy of SGX945 (dusquetide) for the treatment of aphthous oral and genital ulcers in Behçet's syndrome. This was an open-label pilot study of intravenous dusquetide in patients with Behçet's Syndrome who had at least 2 active oral and/or 1 active genital ulcer(s) at enrolment. Participants were treated twice weekly for 4 weeks and then followed for an additional 4 weeks. Efficacy assessments included number and pain of oral and genital ulcers, overall disease activity assessed using Behçet's Syndrome Current Activity Form and Behçet's Syndrome Activity Scale and health-related quality of life assessed using Behçet's Syndrome Quality of Life Index. Eight participants with oral ulcers were enrolled. Seven of 8 participants reported a perceived benefit including reduction in number, duration, and pain of oral ulcers. Comparison to historical placebo groups demonstrated a reduction in the number of ulcers, time to resolution of ulcers, area under the curve of the ulcer-days, oral pain and baseline quality of life metrics. The treatments were well-tolerated with no treatment-related AEs and no serious or severe adverse events recorded. This small pilot study illustrates the potential efficacy and tolerability of SGX945 in patients with Behçet's syndrome who had ulcers despite being on colchicine maintenance therapy. The results justify further development of SGX945 for the treatment of Behçet's syndrome. Clinicaltrials.gov; NCT06386744.31:T95f,Abstract Objectives The study was designed to obtain a preliminary assessment of the safety and efficacy of SGX945 (dusquetide) for the treatment of aphthous oral and genital ulcers in Behçet’s syndrome. Methods This was an open-label pilot study of intravenous dusquetide in patients with Behçet’s syndrome who had at least two active oral and/or one active genital ulcer(s) at enrolment. Participants were treated twice weekly for 4 weeks and then followed for an additional 4 weeks. Efficacy assessments included number and pain of oral and genital ulcers, overall disease activity assessed using Behçet’s Syndrome Current Activity Form and Behçet’s Syndrome Activity Scale and health-related quality of life assessed using Behçet’s Syndrome Quality of Life Index. Results Eight participants with oral ulcers were enrolled. Seven of eight participants reported a perceived benefit including reduction in number, duration and pain of oral ulcers. Comparison to historical placebo groups demonstrated a reduction in the number of ulcers, time to resolution of ulcers, area under the curve of the ulcer-days, oral pain and baseline quality of life metrics. The treatments were well-tolerated with no treatment-related AEs and no serious or severe adverse events recorded. Conclusion This small pilot study illustrates the potential efficacy and tolerability of SGX945 in patients with Behçet’s syndrome who had ulcers despite being on colchicine maintenance therapy. The results justify further development of SGX945 for the treatment of Behçet’s syndrome. Clinical trial registration Clinicaltrials.gov, http://clinicaltrials.gov, NCT06386744. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"SGX945: brand Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on SGX945 (brand). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/brand/SGX945\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Brands\",\"item\":\"https://www.reachrx.ai/hub/tag/brand\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"SGX945\",\"item\":\"https://www.reachrx.ai/hub/tag/brand/SGX945\"}]}}"}}]],["$","$L2f",null,{"title":"SGX945: Research & Clinical Takeaways","description":"See clinical studies on SGX945 — efficacy, safety signals, dosing, and head-to-head results.","papers":[{"doi":"10.1093/rheumatology/keaf682","pmid":"41400947","title":"Results from a pilot study of dusquetide for the treatment of aphthous ulcers associated with Behçet's syndrome","journal_title":"Rheumatology","journal_issn":"1462-0324","published_at":"2025-12-16T00:00:00.000Z","url":"https://doi.org/10.1093/rheumatology/keaf682","source_score":18,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-12-29","doi":"10.1093/rheumatology/keaf682","days":"30","issn":"1462-0324","rank":"5","field":"Clinical Medicine","score":"18","category":"Rheumatology","categories":["Rheumatology"],"_categories":["Rheumatology"]},"pubmed":{"doi":"10.1093/rheumatology/keaf682","title":"Results from a pilot study of dusquetide for the treatment of aphthous ulcers associated with Behçet syndrome.","journal":"Rheumatology (Oxford, England)","methods":"","results":"Eight participants with oral ulcers were enrolled. Seven of 8 participants reported a perceived benefit including reduction in number, duration, and pain of oral ulcers. Comparison to historical placebo groups demonstrated a reduction in the number of ulcers, time to resolution of ulcers, area under the curve of the ulcer-days, oral pain and baseline quality of life metrics. The treatments were well-tolerated with no treatment-related AEs and no serious or severe adverse events recorded.","abstract":"$30","keywords":["Behçet’s Syndrome","dusquetide","genital ulcers","innate immunity","oral ulcers"],"pubmed_id":"41400947","conclusions":"This small pilot study illustrates the potential efficacy and tolerability of SGX945 in patients with Behçet's syndrome who had ulcers despite being on colchicine maintenance therapy. The results justify further development of SGX945 for the treatment of Behçet's syndrome.","publication_date":"2025-12-16T00:00:00"},"crossref":{"DOI":"10.1093/rheumatology/keaf682","URL":"https://doi.org/10.1093/rheumatology/keaf682","ISSN":["1462-0324","1462-0332"],"link":[{"URL":"https://academic.oup.com/rheumatology/advance-article-pdf/doi/10.1093/rheumatology/keaf682/65924990/keaf682.pdf","content-type":"application/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https://academic.oup.com/rheumatology/advance-article-pdf/doi/10.1093/rheumatology/keaf682/65924990/keaf682.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Results from a pilot study of dusquetide for the treatment of aphthous ulcers associated with Behçet's syndrome"],"author":[{"given":"Oreola","family":"Donini","sequence":"first","affiliation":[{"name":"Soligenix, Inc. , Princeton, NJ,"}]},{"given":"Bercemhan","family":"Sulu","sequence":"additional","affiliation":[{"name":"Cerrahpaşa Medical Faculty, Division of Rheumatology, Department of Internal Medicine, Istanbul University – Cerrahpaşa , Istanbul, Türkiye"}]},{"given":"Christopher","family":"Pullion","sequence":"additional","affiliation":[{"name":"Soligenix, Inc. , Princeton, NJ,"}]},{"given":"Adam","family":"Rumage","sequence":"additional","affiliation":[{"name":"Soligenix, Inc. , Princeton, NJ,"}]},{"given":"Richard","family":"Straube","sequence":"additional","affiliation":[{"name":"Soligenix, Inc. , Princeton, NJ,"}]},{"given":"Christopher","family":"Schaber","sequence":"additional","affiliation":[{"name":"Soligenix, Inc. , Princeton, NJ,"}]},{"given":"Gülen","family":"Hatemi","sequence":"additional","affiliation":[{"name":"Cerrahpaşa Medical Faculty, Division of Rheumatology, Department of Internal Medicine, Istanbul University – Cerrahpaşa , Istanbul, Türkiye"}]}],"funder":[{"name":"Soligenix, Inc"}],"issued":{"date-parts":[[2025,12,16]]},"member":"286","prefix":"10.1093","source":"Crossref","volume":null,"created":{"date-time":"2025-12-15T12:29:52Z","timestamp":1765801792000,"date-parts":[[2025,12,15]]},"indexed":{"date-time":"2025-12-28T08:12:53Z","timestamp":1766909573393,"date-parts":[[2025,12,28]]},"license":[{"URL":"https://creativecommons.org/licenses/by-nc/4.0/","start":{"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000,"date-parts":[[2025,12,16]]},"delay-in-days":0,"content-version":"am"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaf682/8381546"}},"subtitle":[],"deposited":{"date-time":"2025-12-28T08:11:45Z","timestamp":1766909505000,"date-parts":[[2025,12,28]]},"issn-type":[{"type":"print","value":"1462-0324"},{"type":"electronic","value":"1462-0332"}],"published":{"date-parts":[[2025,12,16]]},"publisher":"Oxford University Press (OUP)","reference":[{"DOI":"10.55563/clinexprheumatol/ra8ize","key":"2025122803113688100_keaf682-B1","year":"2021","issue":null,"author":"Hatemi","volume":"39(Suppl 132)","first-page":"80","unstructured":null,"article-title":"Apremilast for oral ulcers associated with active Behçet’s syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial","journal-title":"Clin Exp Rheumatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"2025122803113688100_keaf682-B2","year":"2020","issue":null,"author":"Hatemi","volume":"38(Suppl 127)","first-page":"3","unstructured":null,"article-title":"One year in review 2020: behçet’s syndrome","journal-title":"Clin Exp Rheumatol","doi-asserted-by":null},{"DOI":"10.1038/nrrheum.2017.208","key":"2025122803113688100_keaf682-B3","year":"2018","issue":null,"author":"Yazici","volume":"14","first-page":"107","unstructured":null,"article-title":"Behçet syndrome: a contemporary view","journal-title":"Nat Rev Rheumatol","doi-asserted-by":"crossref"},{"DOI":"10.1186/s13075-021-02615-7","key":"2025122803113688100_keaf682-B4","year":"2021","issue":null,"author":"Hammam","volume":"23","first-page":"224","unstructured":null,"article-title":"Epidemiology and treatment of Behcet’s disease in the USA: insights from the Rheumatology Informatics System for Effectiveness (RISE) Registry with a comparison with other published cohorts from endemic regions","journal-title":"Arthritis Res Ther","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(23)02629-6","key":"2025122803113688100_keaf682-B5","year":"2024","issue":null,"author":"Emmi","volume":"403","first-page":"1093","unstructured":null,"article-title":"Behçet’s syndrome","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1080/03009742.2021.1885735","key":"2025122803113688100_keaf682-B6","year":"2021","issue":null,"author":"Leccese","volume":"50","first-page":"475","unstructured":null,"article-title":"Clinical phenotypes of Behcet’s syndrome in a large cohort of Italian patients: focus on gender differences","journal-title":"Scand J Rheumatol","doi-asserted-by":"crossref"},{"DOI":"10.1002/art.42486","key":"2025122803113688100_keaf682-B7","year":"2023","issue":null,"author":"Le Joncour","volume":"75","first-page":"1628","unstructured":null,"article-title":"Reduction of neutrophil activation by phosphodiesterase 4 blockade in Behçet’s Disease","journal-title":"Arthritis Rheumatol","doi-asserted-by":"crossref"},{"DOI":"10.3389/fmed.2023.1055753","key":"2025122803113688100_keaf682-B8","year":"2023","issue":null,"author":"Shimizu","volume":"10","first-page":"1055753","unstructured":null,"article-title":"Innate immune responses in Behçet disease and relapsing polychondritis","journal-title":"Front Med (Lausanne)","doi-asserted-by":"crossref"},{"DOI":"10.3389/fimmu.2022.852297","key":"2025122803113688100_keaf682-B9","year":"2022","issue":null,"author":"Hirahara","volume":"13","first-page":"852297","unstructured":null,"article-title":"The roles of monocytes and macrophages in Behçet’s Disease with focus on M1 and M2 polarization","journal-title":"Front Immunol","doi-asserted-by":"crossref"},{"DOI":"10.3389/fimmu.2023.1109147","key":"2025122803113688100_keaf682-B10","year":"2023","issue":null,"author":"Li","volume":"14","first-page":"1109147","unstructured":null,"article-title":"Chemokines and chemokine receptors in Behçet’s disease","journal-title":"Front Immunol","doi-asserted-by":"crossref"},{"DOI":"10.1136/annrheumdis-2019-215672","key":"2025122803113688100_keaf682-B11","year":"2020","issue":null,"author":"Hellmich","volume":"79","first-page":"19","unstructured":null,"article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","journal-title":"Ann Rheum Dis","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa1816594","key":"2025122803113688100_keaf682-B12","year":"2019","issue":null,"author":"Hatemi","volume":"381","first-page":"1918","unstructured":null,"article-title":"Trial of apremilast for oral ulcers in Behçet’s Syndrome","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jbiotec.2016.03.032","key":"2025122803113688100_keaf682-B13","year":"2016","issue":null,"author":"North","volume":"226","first-page":"24","unstructured":null,"article-title":"A novel approach for emerging and antibiotic resistant infections: innate Defense Regulators as an agnostic therapy","journal-title":"J Biotechnol","doi-asserted-by":"crossref"},{"DOI":"10.1074/jbc.C109.073627","key":"2025122803113688100_keaf682-B14","year":"2009","issue":null,"author":"Yu","volume":"284","first-page":"36007","unstructured":null,"article-title":"Sequestosome-1/p62 is the key intracellular target of innate defense regulator peptide","journal-title":"J Biol Chem","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jbiotec.2016.10.010","key":"2025122803113688100_keaf682-B15","year":"2016","issue":null,"author":"Kudrimoti","volume":"239","first-page":"115","unstructured":null,"article-title":"Randomized, placebo-controlled phase 2a clinical and preclinical data demonstrating a significant and consistent reduction in duration of oral mucositis with a novel innate defense regulator","journal-title":"J Biotechnol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.str.2022.05.003","key":"2025122803113688100_keaf682-B16","year":"2022","issue":null,"author":"Zhang","volume":"30","first-page":"1055","unstructured":null,"article-title":"Dusquetide modulates innate immune response through binding to p62","journal-title":"Structure","doi-asserted-by":"crossref"},{"DOI":null,"key":"2025122803113688100_keaf682-B17","year":"2004","issue":null,"author":"Gilworth","volume":"31","first-page":"931","unstructured":null,"article-title":"Development of the BD-QoL: a quality of life measure specific to Behcet’s disease","journal-title":"J Rheumatol","doi-asserted-by":null},{"DOI":"10.1093/rheumatology/38.8.728","key":"2025122803113688100_keaf682-B18","year":"1999","issue":null,"author":"Bhakta","volume":"38","first-page":"728","unstructured":null,"article-title":"Behcet’s disease: evaluation of a new instrument to measure clinical activity","journal-title":"Rheumatology (Oxford)","doi-asserted-by":"crossref"},{"DOI":null,"key":"2025122803113688100_keaf682-B19","year":"2008","issue":null,"author":"Forbess","volume":"67","first-page":"360","unstructured":null,"article-title":"Behcet’s Syndrome Activity Score (BSAS): a new disease activity assessment tool, composed of patient-derived measures only, is strongly correlated with the Bechcet’s Disease Current Activity Form (BDCAF)","journal-title":"Ann Rheum Dis","doi-asserted-by":null}],"short-title":[],"article-number":"keaf682","content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["Rheumatology"],"reference-count":19,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,12,16]]},"references-count":19,"short-container-title":[],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1093/rheumatology/keaf682","is_oa":false,"title":"Results from a pilot study of dusquetide for the treatment of aphthous ulcers associated with Behçet's syndrome","updated":"2025-12-30T00:50:24+00:00","published_date":"2025-12-15","best_oa_location":null}},"created_at":"2026-01-11T11:19:33.869Z","updated_at":"2026-01-21T12:05:26.220Z","tags":[{"paper_doi":"10.1093/rheumatology/keaf682","tag_type":"brand","value":"SGX945","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keaf682","tag_type":"category","value":"Rheumatology","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keaf682","tag_type":"condition","value":"Behçet's Disease","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keaf682","tag_type":"generic","value":"dusquetide","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keaf682","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keaf682","tag_type":"sample_size","value":"n=8","value_numeric":8},{"paper_doi":"10.1093/rheumatology/keaf682","tag_type":"study_design","value":"Open-Label Single-Arm Trial","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keaf682","tag_type":"warning","value":"Genital-ulcer efficacy was not detailed despite inclusion criteria allowing genital ulcers.","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keaf682","tag_type":"warning","value":"Only abstract-level data were available, with no numerical effect sizes reported.","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keaf682","tag_type":"warning","value":"Study design classification is approximate; this was a single-arm open-label pilot using historical comparators.","value_numeric":null}],"summaries":{"what_studied":"Open-label pilot of intravenous dusquetide (SGX945) given twice weekly for 4 weeks with 4-week follow-up in Behçet’s syndrome patients with active oral and/or genital ulcers; outcomes included ulcer count and pain, disease activity scores, and quality of life.","key_result":"Eight participants with oral ulcers were enrolled; 7/8 reported perceived benefit (fewer, less painful, shorter-duration oral ulcers). Compared with historical placebo groups, there were reductions in ulcer number, time to resolution, ulcer-day AUC, oral pain, and baseline quality-of-life metrics; no treatment-related AEs and no serious or severe AEs were recorded.","limitations":"Very small single-arm, open-label study (n=8) with comparisons to historical placebo, limiting causal inference. Short treatment and follow-up (4+4 weeks), and genital-ulcer outcomes were not specifically quantified.","practice_takeaway":"Dusquetide (SGX945) showed perceived symptom improvement and was well tolerated in a small cohort of Behçet’s patients with ulcers despite colchicine, but evidence is preliminary; reserve judgment pending randomized trials."}}],"initialOffset":1,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"brand","value":"SGX945"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Brands","href":"/hub/tag/brand"},{"name":"SGX945"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"brand","hub_tag_value":"SGX945"}}}]]

Papers